Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 213

References for PMC Articles for PubMed (Select 20190787)

1.

Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine.

Poirier A, Funk C, Scherrmann JM, Lavé T.

Mol Pharm. 2009 Nov-Dec;6(6):1716-33. doi: 10.1021/mp8002495.

PMID:
19739673
2.

The role of transporters in the pharmacokinetics of orally administered drugs.

Shugarts S, Benet LZ.

Pharm Res. 2009 Sep;26(9):2039-54. doi: 10.1007/s11095-009-9924-0. Epub 2009 Jun 30. Review.

3.

Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin.

Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, Urban TJ, Chen L, Yee SW, Choi JH, Huang Y, Brett CM, Burchard EG, Giacomini KM.

Pharmacogenet Genomics. 2009 Jul;19(7):497-504. doi: 10.1097/FPC.0b013e32832cc7e9.

4.

ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.

Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M.

Clin Pharmacol Ther. 2009 Aug;86(2):197-203. doi: 10.1038/clpt.2009.79. Epub 2009 May 27.

PMID:
19474787
5.

Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia.

Sanna S, Busonero F, Maschio A, McArdle PF, Usala G, Dei M, Lai S, Mulas A, Piras MG, Perseu L, Masala M, Marongiu M, Crisponi L, Naitza S, Galanello R, Abecasis GR, Shuldiner AR, Schlessinger D, Cao A, Uda M.

Hum Mol Genet. 2009 Jul 15;18(14):2711-8. doi: 10.1093/hmg/ddp203. Epub 2009 May 6.

6.

Drug interactions at the blood-brain barrier: fact or fantasy?

Eyal S, Hsiao P, Unadkat JD.

Pharmacol Ther. 2009 Jul;123(1):80-104. doi: 10.1016/j.pharmthera.2009.03.017. Epub 2009 Apr 22. Review.

7.

Prediction of the hepatic and renal clearance of transporter substrates in rats using in vitro uptake experiments.

Watanabe T, Maeda K, Kondo T, Nakayama H, Horita S, Kusuhara H, Sugiyama Y.

Drug Metab Dispos. 2009 Jul;37(7):1471-9. doi: 10.1124/dmd.108.026062. Epub 2009 Apr 13.

8.

Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study.

Zhou K, Donnelly LA, Kimber CH, Donnan PT, Doney AS, Leese G, Hattersley AT, McCarthy MI, Morris AD, Palmer CN, Pearson ER.

Diabetes. 2009 Jun;58(6):1434-9. doi: 10.2337/db08-0896. Epub 2009 Mar 31.

9.

Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding.

Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G.

Science. 2009 Mar 27;323(5922):1718-22. doi: 10.1126/science.1168750.

10.

In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney.

Kusuhara H, Sugiyama Y.

Drug Metab Pharmacokinet. 2009;24(1):37-52. Review.

11.

ABCG2: a perspective.

Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, Bates SE.

Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13. doi: 10.1016/j.addr.2008.11.003. Epub 2008 Dec 16. Review.

12.

QSAR analysis and molecular modeling of ABCG2-specific inhibitors.

Nicolle E, Boumendjel A, Macalou S, Genoux E, Ahmed-Belkacem A, Carrupt PA, Di Pietro A.

Adv Drug Deliv Rev. 2009 Jan 31;61(1):34-46. doi: 10.1016/j.addr.2008.10.004. Epub 2008 Dec 16. Review.

PMID:
19135106
13.

Ins and outs of the ABCG2 multidrug transporter: an update on in vitro functional assays.

Hegedus C, Szakács G, Homolya L, Orbán TI, Telbisz A, Jani M, Sarkadi B.

Adv Drug Deliv Rev. 2009 Jan 31;61(1):47-56. doi: 10.1016/j.addr.2008.09.007. Epub 2008 Dec 24. Review.

PMID:
19135105
14.

Silencing the breast cancer resistance protein expression and function in caco-2 cells using lentiviral vector-based short hairpin RNA.

Zhang W, Li J, Allen SM, Weiskircher EA, Huang Y, George RA, Fong RG, Owen A, Hidalgo IJ.

Drug Metab Dispos. 2009 Apr;37(4):737-44. doi: 10.1124/dmd.108.023309. Epub 2009 Jan 8.

15.

Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters.

Leuthold S, Hagenbuch B, Mohebbi N, Wagner CA, Meier PJ, Stieger B.

Am J Physiol Cell Physiol. 2009 Mar;296(3):C570-82. doi: 10.1152/ajpcell.00436.2008. Epub 2009 Jan 7.

16.

Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice.

Vlaming ML, Lagas JS, Schinkel AH.

Adv Drug Deliv Rev. 2009 Jan 31;61(1):14-25. doi: 10.1016/j.addr.2008.08.007. Epub 2008 Dec 7. Review.

PMID:
19118589
18.

Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors.

Abe K, Bridges AS, Brouwer KL.

Drug Metab Dispos. 2009 Mar;37(3):447-52. doi: 10.1124/dmd.108.023465. Epub 2008 Dec 15.

19.
20.

Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide's opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein.

Kurnik D, Sofowora GG, Donahue JP, Nair UB, Wilkinson GR, Wood AJ, Muszkat M.

Anesthesiology. 2008 Dec;109(6):1092-9. doi: 10.1097/ALN.0b013e31818d8f28.

PMID:
19034106
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk